The Sandexis team are highly experienced scientists with expertise in the discovery and development of new experimental drugs across a range of modalities and therapeutic indications. This experience has been gained within large pharma organisations and as independent consultants working with a broad range of clients across the globe

Karl Gibson PhD CChem FRSC

Karl obtained his degree and PhD in Chemistry from the University of Cambridge. He spent 5 years as a medicinal chemist at Merck’s Neuroscience Research Centre followed by 9 years at Pfizer, leading medicinal chemistry teams across the Pain, Urology and Infectious Disease therapeutic areas. Karl co-founded Sandexis Medicinal Chemistry in 2011.

Karl has taught medicinal chemistry at Imperial College, Oxford University, the University of Kent and is a visiting lecturer at the University of Sheffield.

Read Karl’s Publications

Gavin Whitlock PhD CChem FRSC

Gavin obtained his degree and PhD in Chemistry from the University of Nottingham.  He then carried out postdoctoral research at Oxford University and the California Institute of Technology.  Gavin spent 14 years as a medicinal chemist at Pfizer, working across multiple disease areas and gene families and in that time delivered multiple preclinical candidates. Gavin co-founded Sandexis Medicinal Chemistry in 2011.

Read Gavin’s Publications

James Mills PhD FRSC

James obtained his degree and PhD in the Pharmacology Department at the University of Cambridge. He then stayed at Cambridge for postdoctoral research in a collaboration with Imperial College and Rhône-Poulenc Rorer. James spent 12 years at Pfizer as a computational chemist, supporting over 100 projects across all stages of the drug discovery process. James co-founded Sandexis Medicinal Chemistry in 2011.

James has taught computational chemistry at the University of Kent.

Read James’s publications

 

Paul Glossop CChem FRSC

Paul graduated from the University of Nottingham with a BSc in Chemistry. He joined Pfizer in 1993 and worked in the medicinal chemistry department for 18 years, where he was involved in the delivery of multiple clinical candidates, including two that reached positive clinical proof-of-concept. He was the recipient of the ACS Technical Achievement in Organic Chemistry Award in 2010. After leaving Pfizer Paul spent 1 year as a medical writer at ApotheCom ScopeMedical, a global medical communications agency. Paul joined Sandexis in 2013 as a Senior Medicinal Chemist.

Read Paul’s publications